JP5883222B2 - 心的外傷後ストレス障害の治療のためのテトラヒドロキノリン誘導体 - Google Patents

心的外傷後ストレス障害の治療のためのテトラヒドロキノリン誘導体 Download PDF

Info

Publication number
JP5883222B2
JP5883222B2 JP2010528515A JP2010528515A JP5883222B2 JP 5883222 B2 JP5883222 B2 JP 5883222B2 JP 2010528515 A JP2010528515 A JP 2010528515A JP 2010528515 A JP2010528515 A JP 2010528515A JP 5883222 B2 JP5883222 B2 JP 5883222B2
Authority
JP
Japan
Prior art keywords
phenyl
treatment
compound
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010528515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500550A5 (enExample
JP2011500550A (ja
Inventor
ジェンク フランソワ
ジェンク フランソワ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40467356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5883222(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of JP2011500550A publication Critical patent/JP2011500550A/ja
Publication of JP2011500550A5 publication Critical patent/JP2011500550A5/ja
Application granted granted Critical
Publication of JP5883222B2 publication Critical patent/JP5883222B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010528515A 2007-10-10 2008-10-09 心的外傷後ストレス障害の治療のためのテトラヒドロキノリン誘導体 Expired - Fee Related JP5883222B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2007/054130 2007-10-10
IB2007054130 2007-10-10
PCT/IB2008/054138 WO2009047723A2 (en) 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders

Publications (3)

Publication Number Publication Date
JP2011500550A JP2011500550A (ja) 2011-01-06
JP2011500550A5 JP2011500550A5 (enExample) 2011-10-20
JP5883222B2 true JP5883222B2 (ja) 2016-03-09

Family

ID=40467356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010528515A Expired - Fee Related JP5883222B2 (ja) 2007-10-10 2008-10-09 心的外傷後ストレス障害の治療のためのテトラヒドロキノリン誘導体

Country Status (27)

Country Link
US (1) US9532985B2 (enExample)
EP (1) EP2207550B1 (enExample)
JP (1) JP5883222B2 (enExample)
KR (1) KR101733247B1 (enExample)
CN (1) CN101820878B (enExample)
AR (1) AR068768A1 (enExample)
AU (1) AU2008309194B2 (enExample)
BR (1) BRPI0818617A2 (enExample)
CA (1) CA2699504C (enExample)
CY (1) CY1114799T1 (enExample)
DK (1) DK2207550T3 (enExample)
EA (1) EA017443B1 (enExample)
ES (1) ES2444418T3 (enExample)
HR (1) HRP20140214T1 (enExample)
IL (1) IL204838A (enExample)
MA (1) MA31800B1 (enExample)
MX (1) MX2010003711A (enExample)
MY (1) MY153044A (enExample)
NZ (1) NZ585086A (enExample)
PE (1) PE20091010A1 (enExample)
PL (1) PL2207550T3 (enExample)
PT (1) PT2207550E (enExample)
SI (1) SI2207550T1 (enExample)
TW (1) TWI428129B (enExample)
UA (1) UA99150C2 (enExample)
WO (1) WO2009047723A2 (enExample)
ZA (1) ZA201003251B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009127842A (ru) 2006-12-22 2011-01-27 Актелион Фармасьютиклз Лтд (Ch) ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРОИМИДАЗО[1.5-а]ПИРАЗИНА
US20110105514A1 (en) 2008-06-25 2011-05-05 Hamed Aissaoui 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist
JP5744203B2 (ja) 2010-08-24 2015-07-08 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体
MY160969A (en) 2010-09-22 2017-03-31 Eisai R&D Man Co Ltd Cyclopropane compounds
CN103201261A (zh) 2010-11-10 2013-07-10 埃科特莱茵药品有限公司 用作为食欲素受体拮抗剂的内酰胺衍生物
WO2012085852A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides
WO2012110986A1 (en) 2011-02-18 2012-08-23 Actelion Pharmaceuticals Ltd Novel pyrazole and imidazole derivatives useful as orexin antagonists
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
SG11201401665WA (en) 2011-11-08 2014-09-26 Actelion Pharmaceuticals Ltd 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
LT2855453T (lt) 2012-06-04 2017-02-27 Actelion Pharmaceuticals Ltd. Benzimidazolo prolino dariniai
US9493446B2 (en) 2012-10-10 2016-11-15 Actelion Pharmaceuticals Ltd. Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
PT3077389T (pt) 2013-12-03 2017-12-15 Idorsia Pharmaceuticals Ltd Forma cristalina de (s)-(2-(6-cloro-7-metil-1hbenzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona e a sua utilização como como antagonistas do receptor de orexina
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
RU2703297C2 (ru) 2014-10-23 2019-10-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Композиции и способы для лечения бессонницы
CN115710250A (zh) * 2017-08-01 2023-02-24 博健制药有限责任公司 一种食欲素受体拮抗剂的晶型及其制备方法和用途
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020007977A1 (en) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd 7-trifluoromethyl-[1,4]diazepan derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
TW202400149A (zh) 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4009460B2 (ja) 2000-03-14 2007-11-14 アクテリオン ファマシューティカルズ リミテッド １，２，３，４−テトラヒドロイソキノリン誘導体
ATE435210T1 (de) * 2003-03-26 2009-07-15 Actelion Pharmaceuticals Ltd Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten
HRP20150371T1 (hr) * 2004-03-01 2015-05-08 Actelion Pharmaceuticals Ltd. Supstituirani derivati 1,2,3,4-tetrahidroizokinolina
US7501395B2 (en) * 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
AU2007226203A1 (en) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist

Also Published As

Publication number Publication date
MY153044A (en) 2014-12-31
MX2010003711A (es) 2010-04-30
TWI428129B (zh) 2014-03-01
CY1114799T1 (el) 2016-12-14
WO2009047723A2 (en) 2009-04-16
MA31800B1 (fr) 2010-10-01
SI2207550T1 (sl) 2014-03-31
EP2207550B1 (en) 2013-12-11
NZ585086A (en) 2012-03-30
CA2699504C (en) 2015-11-24
US9532985B2 (en) 2017-01-03
PE20091010A1 (es) 2009-08-08
AR068768A1 (es) 2009-12-02
KR20100065203A (ko) 2010-06-15
DK2207550T3 (da) 2014-01-27
IL204838A0 (en) 2010-11-30
TW200932231A (en) 2009-08-01
EA201000557A1 (ru) 2010-10-29
CN101820878B (zh) 2012-02-01
PT2207550E (pt) 2014-02-07
HK1145440A1 (en) 2011-04-21
CN101820878A (zh) 2010-09-01
WO2009047723A3 (en) 2009-05-28
AU2008309194A1 (en) 2009-04-16
BRPI0818617A2 (pt) 2015-04-07
PL2207550T3 (pl) 2014-05-30
AU2008309194B2 (en) 2013-10-03
UA99150C2 (ru) 2012-07-25
IL204838A (en) 2014-09-30
EP2207550A2 (en) 2010-07-21
ZA201003251B (en) 2011-07-27
KR101733247B1 (ko) 2017-05-08
EA017443B1 (ru) 2012-12-28
ES2444418T3 (es) 2014-02-25
US20100234420A1 (en) 2010-09-16
HRP20140214T1 (hr) 2014-04-11
JP2011500550A (ja) 2011-01-06
CA2699504A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
JP5883222B2 (ja) 心的外傷後ストレス障害の治療のためのテトラヒドロキノリン誘導体
JP5582535B2 (ja) 点眼投与による神経疾患または精神神経疾患の治療または予防
JP5456687B2 (ja) ニコチン作動薬を含む組成物及びそれを用いる方法
JP2003510273A (ja) 神経障害性の疼痛の治療のためのレチガビンの使用
EA019354B1 (ru) Применение димирацетама для лечения хронической боли
JP2011522017A (ja) ニコチン受容体の部分アゴニストとアセチルコリンエステラーゼ阻害剤との組み合わせ、これらを含有する医薬組成物、および認知障害の処置におけるこれらの使用
IL257314A (en) A selected amide of gamma-hydroxybutyric acid and its uses in the treatment of alcohol abuse
KR101187461B1 (ko) 각성을 향상시키는 방법
AU735980B2 (en) A method of treating liver disease and like indications with vasodilating agents
TW544311B (en) Therapeutic or preventive agent for intractable epilepsies
JP2005507411A (ja) 下肢静止不能症候群の治療における、ニコチン性アセチルコリン受容体アゴニスト。
HK1145440B (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
Sévoz-Couche et al. Antinociceptive effect of cardiopulmonary chemoreceptor and baroreceptor reflex activation in the rat
KR102040639B1 (ko) 히스타민-3 수용체 역효능제, 아세틸콜린에스테라제 저해제 및 nmda 수용체 길항제의 3중 조합물
KR100350156B1 (ko) 혈관확장제로간질환및관련증상을치료하는방법 및 이에 사용되는 조성물
WO2025102989A1 (zh) 靶向O-GlcNAc糖苷水解酶抑制剂促进髓鞘再生
JP2023539391A (ja) セスキテルペンラクトン系化合物の視神経炎治療薬の製造における使用
CN101242836A (zh) 改善觉醒状态的方法
BR112019002645B1 (pt) Combinação, uso da combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer, composição farmacêutica
HK1263278B (en) Triple combination product of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist
HK1263278A1 (en) Triple combination product of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140123

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160205

R150 Certificate of patent or registration of utility model

Ref document number: 5883222

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees